PropertyValue
?:abstract
  • A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
?:creator
?:doi
  • 10.1007/s00005-020-00602-5
?:doi
?:journal
  • Arch_Immunol_Ther_Exp_(Warsz)
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/772db9b88c9e93f3b4fc2b5f6b5a785421d4b0c1.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7850901.xml.json
?:pmcid
?:pmid
?:pmid
  • 33527308.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
?:type
?:year
  • 2021-02-02

Metadata

Anon_0  
expand all